Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 14;56(3):346-354.
doi: 10.2478/raon-2022-0030.

Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer

Marko Bitenc  1 , Tanja Cufer  2 , Izidor Kern  3 , Martina Miklavcic  1 , Sabrina Petrovic  1 , Vida Groznik  4   5 , Aleksander Sadikov  4
Affiliations

Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer

Marko Bitenc et al. Radiol Oncol. .

Abstract

Background: Treatment of early-stage non-small cell lung cancer (NSCLC) is rapidly evolving. When introducing novelties, real-life data on effectiveness of currently used treatment strategies are needed. The present study evaluated outcomes of stage I-IIIA NSCLC patients treated with upfront radical surgery in everyday clinical practice, between 2010-2017.

Patients and methods: Data of 539 consecutive patients were retrieved from a prospective hospital-based registry. All diagnostic, treatment and follow-up procedures were performed at the same thoracic oncology centre according to the valid guidelines. The primary outcome was overall survival (OS) analysed by clinical(c) and pathological(p) TNM (tumour, node, metastases) stage. The impact of clinicopathological characteristics on OS was evaluated using univariable (UVA) and multivariable regression analysis (MVA).

Results: With a median follow-up of 53.9 months, median OS and 5-year OS rate in the overall population were 90.4 months and 64.4%. Five-year OS rates by pTNM stage I, II and IIIA were 70.2%, 60.21%, and 49.9%, respectively. Both cTNM and pTNM stages were associated with OS; but only pTNM retained its independent prognostic value (p = 0.003) in MVA. Agreement between cTNM and pTNM was 69.0%. Next to pTNM, age (p = 0.001) and gender (p = 0.004) retained their independent prognostic value for OS.

Conclusions: The study showed favourable outcomes of resectable stage I-IIIA NSCLC treated with upfront surgery in real-life. Relatively low agreement between cTNM and pTNM stages and independent prognostic value of only pTNM, observed in real-life data, suggest that surgery remains the most accurate provider of the anatomical stage of disease and important upfront therapy.

Keywords: overall survival; prognostic factors; real-life data; resectable NSCLC; upfront surgery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival of patients with completely resected stage I–III A non-small cell lung cancer.
Figure 2
Figure 2
Overall survival by clinical TNM stage (A), pathological TNM stage (B), clinical N stage (C) and pathological N stage (D).
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. doi: 10.3322/caac.21660. et al. - DOI - PubMed
    1. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75. doi: 10.1016/S0140-6736(17)33326-3. et al. - DOI - PMC - PubMed
    1. Zadnik V, Žagar T, Tomšič S, Lokar K, Duratović Konjević A, Zakotnik B. [Survival of cancer patients]. [Slovenian] Ljubljana: Institute of Oncology; 2020.
    1. Montagne F, Guisier F, Venissac N, Baste JM. The role of surgery in lung cancer treatment: present indications and future perspectives – state of the art. Cancers. 2021;13:1–24. doi: 10.3390/cancers13153711. - DOI - PMC - PubMed
    1. Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32:1637–42. doi: 10.1016/J.ANNONC.2021.08.1994. - DOI - PubMed

Publication types